一品红(300723.SZ)：己酮可可碱缓释片获注册证书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of its drug, Ketoconazole Sustained-Release Tablets, which is indicated for peripheral vascular diseases, including intermittent claudication and rest pain [1] Group 1 - The company's wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., has obtained the drug registration certificate for Ketoconazole Sustained-Release Tablets [1] - The approved indication for the drug includes treatment for peripheral vascular diseases [1]